AL

Alentis

7 known investors

alentis.ch ↗

Alentis Therapeutics is a clinical-stage biotech company developing anti-Claudin-1 antibody-drug conjugates (ADCs) and monoclonal antibodies to treat cancer and reverse organ fibrosis. Its clinical pipeline includes the ADC ALE.P02 for squamous cancers and the monoclonal antibody lixudebart for organ fibrosis.

Investors · 7

AV

Avego BioScience CapitalAlpharetta

BI

BioMedPartnersBasel · $648K – $6.5M

FR

Frazier Life SciencesPalo Alto

JE

Jeito CapitalParis

LO

Longitude CapitalMenlo Park · $10M – $30M

OR

OrbiMedNew York · $1M – $75M

RA

RA CapitalBoston

In the news

Alentis Therapeutics Gains $181.4 Million Funding to Advance Anti-Claudin-1 ADCs in Solid Tumors | BioPharm Internationalbiopharminternational.com · Jun 2026Alentis Therapeutics Raises $181.4M in Series D Fundingfinsmes.com · Nov 2024Alentis Therapeutics Raises $181.4 Million in an Oversubscribed Series D Financing to Advance the Clinical Development of Anti-Claudin-1 ADCs in Solid Tumors - Alentis Therapeuticsalentis.ch · Nov 2024Alentis Therapeutics Raises US$105M in Series C Fundingfinsmes.com · Apr 2023Investors - Alentis Therapeuticsalentis.ch · Jul 2020News - Alentis Therapeuticsalentis.ch · Apr 2019